Résultats de la recherche - P Rhodes
- Résultat(s) 1 - 16 résultats de 16
-
1
-
2
-
3
-
4
-
5
-
6
Annals of Internal Medicine par R. T. Senie, Paul Peter Rosen, P. Rhodes, M. L. Lesser, D. W. Kinne
Publié 1992Artigo -
7
-
8
-
9
-
10
Targeted Lipidomics in Drosophila melanogaster Identifies Novel 2-Monoacylglycerols and N-acyl Amides par Giuseppe Tortoriello, Brandon P. Rhodes, Sara M. Takacs, Jordyn Stuart, А. Баснет, Siham Raboune, Theodore S. Widlanski, Patrick Doherty, Tibor Harkany, Heather B. Bradshaw
Publié 2013Artigo -
11
A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. par Thomas Dudler, Denise Cantarelli Machado, Ludger Kolbe, R. R. Annand, Nicholas P. Rhodes, Michael H. Gelb, Kersten K. Koelsch, M. Suter, Birgit A. Helm
Publié 1995Artigo -
12
Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation par Siham Raboune, Jordyn Stuart, Emma Leishman, Sara M. Takacs, Brandon P. Rhodes, А. Баснет, Evan Jameyfield, Douglas McHugh, Theodore S. Widlanski, Heather B. Bradshaw
Publié 2014Artigo -
13
-
14
Ras activation by SOS: Allosteric regulation by altered fluctuation dynamics par Lars Iversen, Hsiung‐Lin Tu, Wan‐Chen Lin, Sune M. Christensen, Steven M. Abel, Jeff Iwig, Hung‐Jen Wu, Jodi Gureasko, Christopher P. Rhodes, Rebecca S. Petit, Scott D. Hansen, Peter Thill, Cheng‐han Yu, Dimitrios Stamou, Arup K. Chakraborty, John Kuriyan, Jay T. Groves
Publié 2014Artigo -
15
Selective RET kinase inhibition for patients with RET-altered cancers par Vivek Subbiah, Vamsidhar Velcheti, Brian B. Tuch, Kevin Ebata, Naifa L. Busaidy, Maria E. Cabanillas, Lori J. Wirth, Sarah J. Stock, Steven G. Smith, Veronique Lauriault, Stefani Corsi-Travali, Dahlia Henry, Mark E. Burkard, R. Hamor, Karyn Bouhana, Shannon L. Winski, Ross Wallace, Dylan P. Hartley, Susan P. Rhodes, Mamatha M. Reddy, Barbara J. Brandhuber, Steven D. Andrews, S. Michael Rothenberg, Alexander Drilon
Publié 2018Artigo -
16
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer par Jay B. Fell, John P. Fischer, Brian R. Baer, James F. Blake, Karyn Bouhana, David M. Briere, Karin Brown, Laurence E. Burgess, Aaron C. Burns, Michael Burkard, Harrah Chiang, Mark J. Chicarelli, Adam W. Cook, John J. Gaudino, Jill Hallin, Lauren Hanson, Dylan P. Hartley, Erik J. Hicken, Gary P. Hingorani, Ronald J. Hinklin, Macedonio J. Mejia, Peter Olson, Jennifer Otten, Susan P. Rhodes, Martha E. Rodriguez, Pavel Y. Savechenkov, Darin Smith, Niranjan Sudhakar, Francis X. Sullivan, Tony P. Tang, Guy Vigers, Lance Wollenberg, James G. Christensen, Matthew A. Marx
Publié 2020Artigo
Outils de recherche:
Sujets similaires
Biochemistry
Biology
Chemistry
Medicine
Gene
Enzyme
Internal medicine
Receptor
Biophysics
Cell
Cell biology
Genetics
In vitro
Organic chemistry
Antibody
Cancer
Cell membrane
Cell signaling
Immunology
Inflammation
Materials science
Membrane
Membrane protein
Microglia
Molecular biology
Nanotechnology
Pharmacology
Philosophy
RNA
RNA polymerase